clinical trial · NCT05397223
A Study of Modified mRNA Vaccines in Healthy Adults
ModernaTX, Inc.·phase1·completed·n = 308
SARS-CoV-2Seasonal InfluenzaRespiratory Syncytial VirusCytomegalovirusmRNA-1273mRNA-1010mRNA-1345FLUAD®mRNA-1647
brief summary
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
started
May 24, 2022
primary completion
Feb 27, 2026
completion
Feb 27, 2026
last updated
Mar 12, 2026
official title
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol